Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer

Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer

Abstract Background Bladder cancer is the 7th cause of death from cancer in men and 10th in women. Metastatic patients have a poor prognosis with a median overall survival of 14 months. Until recently, vinflunine was the only second-line chemotherapy available for patients who relapse. Deregulation...

Full description

Bibliographic Details
Main Authors: Marina Pulido, Guilhem Roubaud, Anne-Laure Cazeau, Hakim Mahammedi, Lionel Vedrine, Florence Joly, Loic Mourey, Christian Pfister, Alejandro Goberna, Barbara Lortal, Carine Bellera, Philippe Pourquier, Nadine Houédé
Format: Article
Language:English
Published: BMC 2018-02-01
Series:BMC Cancer
Subjects:
Metastatic bladder cancer
Clinical trial
Temsirolimus
mTOR
Online Access:http://link.springer.com/article/10.1186/s12885-018-4059-5

Internet

http://link.springer.com/article/10.1186/s12885-018-4059-5

Similar Items